Alder receives rights to eptinezumab IP from Teva

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) granted Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) rights to IP related to eptinezumab (IV ALD403). Alder also announced that the migraine prevention candidate

Read the full 280 word article

User Sign In